-
In this issue: Tiotropium for uncontrolled asthma, sibutramine pulled from market, incidence and mortality data from WHI, FDA Actions.
-
A study group of 98 patients were enrolled through seven centers to evaluate the efficacy of sildenafil in the treatment of sexual dysfunction associated with the use of selective and nonselective serotonin reuptake inhibitors (SRIs).
-
It seems that at least twice a week we either inadvertently find, or have a pregnant patient referred with a band-like structure that runs north-to-south between the uterine walls. In a non-pregnant uterus this would be called a synechium, but the most common label assigned to this finding in pregnancy is a "sheet."
-
For many years we have been pushing the concept that the earlier that prenatal care is initiated, the better will be the outcome. Since there are certainly data proving that late enrollment makes for worse outcomes, this "the-earlier-the-better" mantra has almost attained bumper sticker status.
-
The authors investigated invasive breast cancer incidence and mortality after a total follow-up of 11 years among the 16,608 postmenopausal women aged 50-79 years with no prior hysterectomy who were randomized to combined oral conjugated equine estrogens (0.625 mg/day) plus medroxyprogesterone acetate (2.5 mg/day) or placebo in the Women's Health Initiative (WHI) HRT study. In the initial reports from the WHI HRT study, breast cancer incidence was increased (hazard rate [HR], 1.26; 95% confidence interval [CI], 1.00-1.59).
-
-
Early Detection and Treatment of Ovarian Cancer Improves Outcome: Right?
-
This trial was a randomized double-blind control trial of 89 women undergoing consecutive removal and replacement of a levonorgestrel-releasing intrauterine device (LNG-IUD). Of note, this study was part of a larger multicenter trial evaluating the bleeding profile and safety with repeat use of a LNG-IUD in women who had used their first device for close to 5 years.
-
FDA Advisory Committee recommends approval of dabigatran, safety of proton pump inhibitors, effectiveness of glucosamine and chondroitin, FDA Actions.
-
Several recent studies examine the contributions of imaging, biomarkers, and neuropsychological testing to a refined understanding of the syndromes collectively known as primary progressive aphasia.
